NCT02333565已完成2 期
Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas.
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- The Progression Free Survival rate
研究概览
简要总结
To determine if combination of everolimus and octreotide exert an anti-tumoral activity in recurrent and/or aggressive meningiomas growth with limited adverse effects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and Female patients ≥ 18 years old with no maximum limited of age
- •Histologically proven meningioma grade II and III; grade I meningioma may also be included, if progression is documented (see criteria 3), particularly in case of skull base location
- •Progression is defined on 2 different MRI as an increase of meningioma's surface ≥ 5% by 3 months period (i.e. an increase of 5% over 3 months, 10% over 6 months, 15% over 9 months...) or as the apparition of a new unequivocal neurological symptom related to the meningioma. We considered as a new unequivocal neurological symptom a new occurring neurological symptom as, for instance, hemiparesia, oculomotor nerve palsy, visual loss, facial nerve palsy, facial neuralgia, directly related to meningioma and suggesting meningioma growth with increase of meningioma compression on neurological structures despite no increasing size on MRIs.
- •Patients must have failed surgery, and not amenable to a new curative intended surgery
- •Patients must have failed radiotherapy and/or radiosurgery
- •Prior chemotherapy is allowed, if progression under the cytotoxic agent is clearly documented. An interval of 4 weeks after the last administration of the cytotoxic agent is warranted. Number of prior chemotherapies is not limited.
- •Patients who have given their written consent
- •Patients affiliated to a social insurance regime
- •Adequate bone marrow function as shown by: Absolute Neutrophil Count ≥ 1.5 x 109/L,
- •Platelets ≥ 100 x 109/L, Hb >9 g/dL
- •Adequate liver function as shown by; serum bilirubin ≤ 1.5 x Upper Limit of Normal; International Normalized Ratio < 1.3; alanine aminotransferase and aspartate aminotransferase ≤ 2.5 x Upper Limit of Normal - Adequate renal function: serum creatinine ≤ 1.5 x Upper Limit of Normal - Fasting serum cholesterol ≤ 300 mg/dL OR ≤ 7.75 mmol/L and fasting triglycerides ≤ 2.5 x Upper Limit of Normal. NOTE: In case one or both of these thresholds are exceeded, the patient can only be included after dyslipidemia treatment initiation.
排除标准
- •Patients with symptomatic lithiasis
- •Contra indication to octreotide and everolimus
- •Women of child-bearing age who are using no effective means of contraception
- •Pregnant or breast-feeding women or adults of reproductive potential who are not using effective birth control methods. If barrier contraceptives are being used, these must be continued throughout the trial by both sexes
- •Patients receiving other investigational agents or who received an investigative drug or therapy within the last 30 days.
- •Known intolerance or hypersensitivity to octreotide, everolimus or other rapamycin (sirolimus, temsirolimus)
- •Uncontrolled diabetes mellitus defined by HbA1c>8.5%
- •Patients who have any severe and/or uncontrolled medical condition:
- •unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction ≤ 6 months prior to inclusion, serious uncontrolled cardiac arrhythmia, active or uncontrolled severe infection, cirrhosis, chronic active hepatitis or chronic persistent hepatitis, severely impaired lung function (spirometry and Diffusing Capacity of the lung for carbon monoxide 50% or less of normal and O2 saturation 88% or less at rest on room air), active, bleeding diathesis
- •Patients receiving chronic treatment with immunosuppressive agent
- •Patients with a known history of HIV seropositivity
- •Patients who have a history of another primary malignancy ≤ 3 years, with the exceptions of non-melanoma skin cancer, and carcinoma in situ of uterine cervix.
- •Females patients who are pregnant or lactating, or are of childbearing potential and not practicing a medically acceptable method of birth control.
研究组 & 干预措施
Combinaison everolimus and octreotide
Experimental
干预措施: Everolimus (Drug)
Combinaison everolimus and octreotide
Experimental
干预措施: Octreotide (Drug)
结局指标
主要结局
The Progression Free Survival rate
时间窗: 36 months
Measured by the number of individuals without progression disease at 6 months, according to Response Assessment in Neuro-Oncology criteria's.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Phase II Study of Everolimus Combined With Octreotide LAR to Treat Advanced GI NETGastrointestinal NeoplasmsNCT01567488Grupo Espanol de Tumores Neuroendocrinos43
已完成
1 期
Study of Everolimus (RAD001) in Combination With LenalidomideSolid Organ MalignanciesAdenoidcystic CarcinomaNeuroendocrine TumorsNCT01218555Emory University44
已完成
2 期
Everolimus added to long acting octreotide as a volume reducing treatment of polycystic livers.polycystic liver disease10019654NL-OMON32654niversitair Medisch Centrum Sint Radboud44
进行中（未招募）
1 期
Everolimus added to long acting octreotide as a volume reducing treatment of polycystic livers. - ELATEIsolated polycystic liver diseaseMedDRA version: 12.1Level: LLTClassification code 10048834Term: Polycystic liver diseaseMedDRA version: 12.1Level: PTClassification code 10048834Term: Polycystic liver diseaseEUCTR2009-016640-39-NLRadboud University Nijmegen Medical Centre44
已完成
2 期
Everolimus and LongActing Octreotide Trial in Polycystic LiversPolycystic Liver DiseaseNCT01157858Radboud University Medical Center44